Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression

Abstract

The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the HAO1 gene, and methods of using such RNAi agents to inhibit expression of HAO1 and methods of treating subjects having, e.g., PH1.

1 . A double stranded RNAi agent that inhibits expression of hydroxyacid oxidase 1 (HAO1) in a cell,
 wherein said double stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region,   wherein said sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the nucleotide sequences of SEQ ID NO:1 SEQ ID NO:2, SEQ ID NO:5, or SEQ ID NO:6 and said antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the nucleotide sequences of SEQ ID NO:3 SEQ ID NO:4, SEQ ID NO:7, or SEQ ID NO:8;   wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand comprise a nucleotide modification, and   wherein at least one strand is conjugated to a ligand.   
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . The double stranded RNAi agent of  claim 1 , wherein at least one of said nucleotide modifications is selected from the group consisting of a 3′-terminal deoxy-thymine (dT) nucleotide modification, a 2′-O-methyl modified nucleotide modification, a 2′-fluoro nucleotide modification, a 2′-deoxy nucleotide modification, a locked nucleotide modification, an abasic nucleotide modification, a 2′-amino nucleotide modification, a 2′-alkyl nucleotide modification, a morpholino nucleotide modification, a phosphoramidate modification, a non-natural base comprising nucleotide modification, a nucleotide comprising a 5′-phosphorothioate group modification, a nucleotide comprising a 5′ phosphate or 5′ phosphate mimic modification, and a terminal nucleotide linked to a cholesteryl derivative or a dodecanoic acid bisdecylamide group modification. 
     
     
         5 .- 17 . (canceled) 
     
     
         18 . The double stranded RNAi agent of  claim 1 , wherein the double-stranded region is 15-30 nucleotide pairs in length. 
     
     
         19 .- 23 . (canceled) 
     
     
         24 . The double stranded RNAi agent of  claim 1 , wherein each strand is independently has-15-30 nucleotides in length. 
     
     
         25 .- 27 . (canceled) 
     
     
         28 . The double stranded RNAi agent of  claim 1 , wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent linker. 
     
     
         29 . The double stranded RNAi agent of  claim 1 , wherein the ligand is 
       
         
           
           
               
               
           
         
       
     
     
         30 . The double stranded RNAi agent of  claim 1 , wherein the ligand is attached to the 3′ end of the sense strand. 
     
     
         31 . The double stranded RNAi agent of  claim 30 , wherein the double stranded RNAi agent is conjugated to the ligand as shown in the following schematic 
       
         
           
           
               
               
           
         
         wherein X is O or S. 
       
     
     
         32 . The double stranded RNAi agent of  claim 1 , wherein said double stranded agent further comprises at least one phosphorothioate or methylphosphonate internucleotide linkage. 
     
     
         33 .- 52 . (canceled) 
     
     
         53 . The double stranded RNAi agent of  claim 1 , wherein said double stranded RNAi agent is selected from the group consisting of the double stranded RNAi agents listed in any one of Tables 1 or 2. 
     
     
         54 .- 66 . (canceled) 
     
     
         67 . An isolated cell containing the double stranded RNAi agent of  claim 1 . 
     
     
         68 . A pharmaceutical composition comprising the double stranded RNAi agent of  claim 1 . 
     
     
         69 .- 73 . (canceled) 
     
     
         74 . A method of inhibiting HAO1 expression in a cell, the method comprising:
 (a) contacting the cell with the double stranded RNAi agent of  claim 1 ; and   (b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of a HAO1 gene, thereby inhibiting expression of the HAO1 gene in the cell.   
     
     
         75 .- 77 . (canceled) 
     
     
         82 . A method of treating a subject having a HAO1 associated disorder, comprising administering to the subject a therapeutically effective amount of the double stranded RNAi agent of  claim 1 . 
     
     
         83 . (canceled) 
     
     
         84 . (canceled) 
     
     
         85 . The method of  claim 82 , wherein the subject is a human. 
     
     
         86 . The method of  claim 85 , wherein the human has Primary Hyperoxaluria Type 1 (PH1). 
     
     
         87 . The method of  claim 82 , wherein the double stranded RNAi agent is administered at a dose of about 0.01 mg/kg to about 10 mg/kg or about 1 mg/kg to about 10 mg/kg. 
     
     
         88 . (canceled) 
     
     
         89 . (canceled) 
     
     
         90 . The method of  claim 87 , wherein the double stranded RNAi agent is administered to the subject subcutaneously. 
     
     
         91 . (canceled) 
     
     
         92 . The method of  claim 87 , wherein the double stranded RNAi agent is administered to the subject in two or more doses. 
     
     
         93 . (canceled) 
     
     
         94 . (canceled)